CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
CytomX Therapeutics (CTMX) Misses Q3 EPS by 2c
November 8, 2022 4:19 PM ESTCytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of ($0.35), $0.02 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $16.92 million versus the consensus estimate of $18.27 million.
For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.
... More